Disc Medicine (IRON) said late Wednesday it priced its public offering of common stock and pre-funded warrants for gross proceeds of about $225.5 million, upsized from the initial offering of $200 million.
The company said it is selling about 3.9 million shares and pre-funded warrants to purchase 181,818 shares. The common shares are being sold at $55 per share, while the warrants are being sold at $54.9999 per warrant.
Underwriters have been granted a 30-day option to purchase up to about $33.8 million additional shares.
Proceeds from the offering, set to close on Friday, would be used to fund research and clinical development of its product candidates, support the potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, and for general corporate purposes, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。